Melanoma treatment is moving toward personalized cancer vaccines designed for each patient’s unique genetic profile. While promising, their use is currently limited by how long they take to produce.
Because these vaccines are custom-made, manufacturing takes about 6 to 9 weeks. This creates a critical waiting period, meaning the treatment works best for patients whose disease is stable during that time.
Patients with low tumor burden or slow-growing melanoma are the best candidates, as they can safely wait for the vaccine to be ready. In contrast, those with aggressive or advanced disease usually cannot wait and need immediate treatment with standard immunotherapies.
Overall, personalized vaccines represent the future of melanoma care, but for now, they are most suitable for carefully selected patients rather than those needing urgent treatment.